Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Sss06

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
P 2 (2)

Trial Status

Not Yet Recruiting2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07891377Phase 2Not Yet RecruitingPrimary

HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies

NCT06854276Phase 2Not Yet RecruitingPrimary

Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

NCT02158169CompletedPrimary

Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology

Showing all 3 trials

Research Network

Common Treatments

  • Sss061
  • Rhepo1
  • Hec53856 Tablet1
  • Rhuepo Injection1

Active Sponsors

  • Shenyang Sunshine Pharmaceutical Co Ltd1
  • Sunshine Lake Pharma Co Ltd1
  • Hospira Now A Wholly Owned Subsidiary Of Pfizer1

Related Conditions

  • Nonmyeloid Malignancies1
  • Nonmyeloid Malignancy1

Activity Timeline